Founded in 2019, JLS Fund is a unique venture capital fund focused primarily on neuroscience, mental health and enabling tools and infrastructure. From Pre-seed and Seed investing to Series A and later-stage secondaries transitioning to buyout.
Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.
ProNovo Therapeutics, leveraging emerging science and cutting-edge technology, to develop novel, precision therapeutics to address urgent unmet needs in the treatment of neuropsychiatric disorders such as Major Depressive Disorder and Schizophrenia.
Reimagines psychoactive natural products as the building blocks for the next generation of neurological products
An award-winning breakthrough wellness platform
Immunis is a clinical-stage biotech company developing multi-active biologics with immune modulating factors that can address age-related diseases and immune dysregulation.
A clinical-stage neuroscience biotech transforming the treatment paradigm of psychiatric diseases.
Light Alliance Summit: Cuba 2026 - An Immersive Journey into Conscious Community & Collective Impact
March 19-22, 2026
Simeon will be speaking at the second annual Light Alliance Summit—an inspiring gathering of global visionaries, conscious leaders, entrepreneurs, investors, and creators committed to co-creating a future defined by abundance, wellness, and meaningful connection.
How many Americans microdosed psychedelics last year? More than you might think! Plus ONWARD completes two implants of its BCI therapy.
Check Out Our Substack!
.png){kind=small}
